Multiple Myeloma is characterized by several structural genomic aberrations. Many of these clinically relevant variations are detectable by FISH. Empire Genomics manufactures probes that can be used for this detection. Both design and probe colors can be customized.

1p1q FISH Probe 1p1q
20 1P1Q-20-GROR

Amplification of CKS1B (1q) can occur in 30% of patients with multiple myeloma. Amplification in this region has shown poor prognosis and shorter progression free survival than patients lacking this abnormality. A deletion in the CDK2NC (1p) region can inactivate an important tumor suppressor gene, and can be found in 15% of multiple myeloma patients4. This deletion can lead to uncontrolled cell proliferation and poor patient prognosis. Both CKS1B and CDK2NC can be detected in a single Empire Genomics FISH assay. The advantage to detection of these probes via FISH is that being on the same chromosome, they will act as controls for each other. This probe can also be used to determine if there is a double-hit of these genes in a single patient.

Chromosome 05 Control Probe Chromosome 5
10 CHR05-10-GR

Trisomies of chromosomes 3 and 5 have been shown to have clinical relevance in patients with multiple myeloma1. Patients with Trisomy 5 have been successfully treated with companion diagnostic drugs. Identification of trisomy 5 in multiple myeloma patients can allow for the proper drug selection to be made. (lenalidomide) Empire Genomics’ control 5 FISH probe can be used to detect copy number variations of chromosome 5. This probe can also be combined with our chromosome 3 FISH probe for a 2-color panel detecting these aberrations.

CCND1-IGH Split FISH Probe

CCND1 is a fusion partner for the clinically relevant IGH gene. IGH contains a variable region that is prone to translocations, but the determination that it has translocated may not be enough to determine prognosis and guide treatment. The Empire Genomics CCND1/IGH FISH probe can be used to determine if IGH has fused with CCND1. This fusion can occur in as many as 23% of patients with an IGH translocation2, so it should be a part of any multiple myeloma FISH panel.

RB1/LAMP1 Dual Color FISH Probe
20 RB1-LAMP1-20-ORGR

Deletion of 13q regions can be detected with karyotype analysis or with FISH, however when detected via a karyotype, clinical relevance is more difficult to determine1. This is due to the limit of detection for karyotyping. FISH analysis allows for the observation of specific regions within 13q, specifically 13q14 and q34 regions (RB1 and LAMP1).

IGH Split FISH Probe
20 IGH-20-GR

IGH is among the most commonly translocated genes in multiple myeloma. IGH contains both a constant region and a variable region. The Empire Genomics IGH FISH probe extends into the variable region so that when there is a translocation, detection is possible. Patients with IGH translocations are less likely to be have hyperdiploidy1, so determination of an IGH translocation via FISH can limit the need for additional testing.

TP53 FISH Probe
20 TP53-20-GR

TP53 is believed to be the clinically relevant and actionable biomarker in the 17p deletion found in many multiple myeloma cases1. This deletion is detectable by hybridizing a FISH probe to the TP53 gene with a control on chromosome 17 to confirm the deletion. This detection can inform treatment as drugs have been linked to the targeting of TP53 aberrations

Request More Information & Your Free Sample

Are you interested in our multicolor kit but still have questions? Send us a message with the specific probes you're interested in and we'll send you a free sample to try out.